Capricor presents HOPE-3 trial data at neurology meeting

April 22, 2026 9:02 AM

Capricor Therapeutics (NASDAQ: CAPR) announced the presentation of data from its Phase 3 HOPE-3 clinical trial of Deramiocel for Duchenne ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found